US · IVA · BIOTECHNOLOGY
Inventiva S.A. (IVA) intrinsic value and stock valuation
$3.14as of 2026-11-21 · Mkt cap 245.36M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Inventiva S.A. DCF and intrinsic value
InvestorsCraft values IVA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IVA’s statements →
Inventiva S.A. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2013–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Enanta Pharmaceuticals, Inc. (ENTA) $7.62
- Orchestra BioMed Holdings, Inc. (OBIO) $6.58
- Cartesian Therapeutics, Inc. (RNAC) $6.14
- Eupraxia Pharmaceuticals Inc. (EPRX) $5.80
- Avalo Therapeutics, Inc. (AVTX) $6.76
- Invivyd, Inc. (IVVD) $0.41
- Tenaya Therapeutics, Inc. (TNYA) $0.29
- Caribou Biosciences, Inc. (CRBU) $0.28
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.48M | $9.2M | $17.5M | $12.2M | $4.19M |
| Operating income | -$-130.95M | -$-97.56M | -$-102.71M | -$-57.11M | -$-52.11M |
| Net income | -$-340.16M | -$-184.21M | -$-110.43M | -$-54.27M | -$-49.64M |
| EPSd | -$-1.82M | -$-3.54M | -$-2.44M | -$-1.31M | -$-1.27M |
| Operating cash flow | -$-100.98M | -$-85.93M | -$-81.61M | -$-44.93M | -$-47.63M |
| Capital expenditure | -$-240K | -$-330K | -$-540K | -$-560K | -$-530K |
| Free cash flow | -$-101.22M | -$-86.26M | -$-82.15M | -$-45.49M | -$-48.16M |
| Total assets | $248.9M | $119M | $69.6M | $116M | $122M |
| Total debt | $59.4M | $54.3M | $37.5M | $34.5M | $10.1M |
| Net debt | -$-39.87M | -$-42.23M | $10.6M | -$-52.22M | -$-76.43M |
| Total equity | -$-29.04M | -$-106.65M | -$-32.03M | $45.5M | $88.9M |
| Cash and short-term investments | $99.3M | $96.6M | $27.3M | $87.8M | $86.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.48M | $9.2M | $17.5M | $12.2M | $4.19M |
| Cost of revenue | $2.8M | $3.88M | -$-20K | $990K | $1.02M |
| Gross profit | $1.51M | $9.2M | $17.5M | $17.1M | $4.19M |
| Research and development expenses | $83.6M | $90.9M | $110M | $60.5M | $48.5M |
| Selling, general and administrative expenses | $53.9M | $17.1M | $15.6M | $15.5M | $11.5M |
| Other expenses | -$-130K | -$-1.22M | -$-5.43M | -$-1.8M | -$-3.66M |
| Operating expenses | $137.4M | $106.8M | $120.2M | $74.2M | $56.3M |
| Cost and expenses | $137.4M | $106.8M | $120.2M | $75.2M | $56.3M |
| Interest income | $2.83M | $1.14M | $940K | $390K | $60K |
| Interest expense | $32.3M | $12.2M | $5.18M | $710K | $140K |
| Depreciation and amortization | $2.8M | $5.2M | $2.6M | $870K | $860K |
| Ebitda | -$-128.15M | -$-166.53M | -$-102.04M | -$-56.29M | -$-52.76M |
| Operating income | -$-130.95M | -$-97.56M | -$-102.71M | -$-57.11M | -$-52.11M |
| Total other income/expenses, net | -$-211.38M | -$-86.34M | -$-7.11M | $2.82M | $2.84M |
| Income before tax | -$-342.33M | -$-183.9M | -$-109.82M | -$-54.29M | -$-49.27M |
| Income tax expense | $20K | $310K | $610K | -$-20K | $360K |
| Net income | -$-340.16M | -$-184.21M | -$-110.43M | -$-54.27M | -$-49.64M |
| Weighted average shares outstanding | $186.8M | $52M | $45.4M | $41.5M | $39.2M |
| Weighted average diluted shares outstanding | $186.8M | $52M | $45.4M | $41.5M | $39.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $99.3M | $96.6M | $27.3M | $87.8M | $86.6M |
| Net receivables | $9.12M | $12.2M | $15.7M | $280K | $11.6M |
| Inventory | $0.00 | $0.00 | $420K | $370K | $390K |
| Total current assets | $243.8M | $111.5M | $48.2M | $106.4M | $115.6M |
| Property, plant and equipment, net | $2.98M | $5M | $9.13M | $7.39M | $3.2M |
| Goodwill and intangible assets | $180K | $50K | $540K | $570K | $770K |
| Long-term investments | $530K | $1.14M | $1.43M | $700K | $1.75M |
| Total non-current assets | $5.04M | $7.46M | $21.4M | $9.62M | $6.41M |
| Total assets | $248.9M | $119M | $69.6M | $116M | $122M |
| Accounts payable | $26M | $32.9M | $37.7M | $19.4M | $14.6M |
| Short-term debt | $32.3M | $5.87M | $5.31M | $5.85M | $1.28M |
| Deferred revenue | $0.00 | $0.00 | $10K | $10K | $0.00 |
| Total current liabilities | $77.4M | $120.7M | $50.2M | $30.7M | $22.9M |
| Long-term debt | $27.5M | $48.5M | $32.2M | $28.7M | $8.84M |
| Deferred revenue, non-current | $130K | $110K | $0.00 | $60K | $0.00 |
| Total non-current liabilities | $200.6M | $104.9M | $51.4M | $39.8M | $10.3M |
| Capital lease obligations | $4.81M | $4.66M | $6.57M | $4.51M | $130K |
| Total liabilities | $277.9M | $225.6M | $101.6M | $70.5M | $33.1M |
| Common stock | $1.93M | $960K | $520K | $420K | $410K |
| Retained earnings | -$-354.14M | -$-184.21M | -$-110.43M | -$-54.27M | -$-49.63M |
| Accumulated other comprehensive income (loss) | -$-204.55M | -$-172.55M | -$-123.99M | -$-74.56M | -$-26.98M |
| Total equity | -$-29.04M | -$-106.65M | -$-32.03M | $45.5M | $88.9M |
| Total investments | $530K | $1.14M | $1.5M | $1.75M | $1.75M |
| Total debt | $59.4M | $54.3M | $37.5M | $34.5M | $10.1M |
| Net debt | -$-39.87M | -$-42.23M | $10.6M | -$-52.22M | -$-76.43M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-340.16M | -$-184.21M | -$-110.43M | -$-54.27M | -$-49.63M |
| Depreciation and amortization | $3.22M | $5.2M | $2.6M | $1.7M | -$-1.29M |
| Stock-based compensation | $26.8M | $3.58M | $3.97M | $2.22M | $2.09M |
| Change in working capital | $6.42M | $1.68M | $17.3M | $5.71M | $980K |
| Accounts receivable | $820K | $2.81M | -$-5.84M | $3.84M | -$-5.32M |
| Inventory | $0.00 | $420K | -$-40K | $20K | -$-70K |
| Accounts payable | $2.46M | $0.00 | $20M | $3.54M | $7.6M |
| Net cash provided by operating activities | -$-100.98M | -$-85.93M | -$-81.61M | -$-44.93M | -$-47.63M |
| Investments in property, plant and equipment | -$-240K | -$-330K | -$-540K | -$-560K | -$-530K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $40K | $90K |
| Net cash used for investing activities | -$-127.93M | $8.74M | -$-7.73M | $8.87M | -$-1.79M |
| Common stock issued | $237.7M | $57.3M | $28.1M | $8.83M | $25.5M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $232M | $145.6M | $29.1M | $37.3M | $25.5M |
| Net change in cash | $14.2M | $69.7M | -$-59.82M | $180K | -$-19.13M |
| Cash at end of period | $99.3M | $96.6M | $26.9M | $86.7M | $86.6M |
| Operating cash flow | -$-100.98M | -$-85.93M | -$-81.61M | -$-44.93M | -$-47.63M |
| Capital expenditure | -$-240K | -$-330K | -$-540K | -$-560K | -$-530K |
| Free cash flow | -$-101.22M | -$-86.26M | -$-82.15M | -$-45.49M | -$-48.16M |
Line items
Line items
Line items
About Inventiva S.A.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
- CEO
- Andrew Obenshain
- Employees
- 73
- Beta
- 0.89
Explore
Frequently asked questions
What is the intrinsic value of Inventiva S.A. (IVA)?
Inventiva S.A. (IVA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is IVA undervalued?
IVA trades at a price of $3.14 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.